The Moscow Clinical Scientific and Practical Center named after A. S. Loginov (under the jurisdiction of the Moscow Department of Health) has been added to the list of medical organizations authorized to manufacture and use biotechnological medicinal products, according to an order published on the official portal of legal acts. This marks the first change to the list since it was approved in December 2024.
The total number of the institutions in the list has reached 19. Eight of them are located in Moscow, three more in Novosibirsk, two in St. Petersburg, and while Obninsk (Kaluga region), Tomsk, Vladivostok, Kazan, Kemerovo, and Irkutsk have one institution each. In the capital, this includes, in particular, the N. N. Blokhin National Medical Research Center of Oncology, the V. A. Nasonova Research Institute of Rheumatology, and the B. V. Petrovsky Russian Scientific Center of Surgery.
According to the legislation, these organizations have the right to “manufacture and use biotechnological drugs tailored for a specific patient, directly within the medical facility where the drug is administered, with compounds synthesized based on genetic tests of material obtained from the patient for whom the drug is produced.”
